Study Background
The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.
This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.
Eligibility Criteria
- Healthy men and non-pregnant women aged 18-65
- Weighing at least 110 pounds
- Normal, healthy adult donors as judged by screening questionnaire
- Nonpregnant
- HIV negative (proof required every 6 months we will conduct test)
- Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)
- The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow
Principal Investigator
-
-
Michael B. Fessler, M.D.
Chief, Clinical Research Branch;
Clinical Director and Chair - Clinical Advisory Committee (CAC);
Principal Investigator -
Tel 984-287-4081
[email protected] -
P.O. Box 12233Mail Drop D2-01Durham, NC 27709
-
-
Stavros Garantziotis, M.D.
Tenure Track Investigator; Immunity, Inflammation, and Disease Laboratory -
Tel 984-287-4412
Fax 919-541-9854
[email protected] -
P.O. Box 12233Mail Drop CU-01Durham, NC 27709